Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma

Originally Published By 2 Minute Medicine®. Reused on ONA with permission.
Share this content:

1. Patients with refractory diffuse large B-cell or follicular lymphoma demonstrated high rates of remission when treated with anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy.

2. Serious adverse events noticed in this cohort included cytokine release syndrome and encephalopathy.

Evidence Rating Level: 3 (Average)

Study Rundown: Diffuse large B-cell lymphoma and follicular lymphoma comprise the two most common types of non-Hodgkin's lymphoma. Both are primarily treated with rituximab-based chemotherapy regimens, however the prognosis for either cancer remains poor for patients that either relapse or are refractory to treatment. Adoptive immunotherapy, which uses T-cells expressing a CAR for B-cell CD19 antigens, has shown promising preliminary results as a treatment option for patients with B-cell cancers. This case-series assessed the efficacy of anti-CD19 CAR expressing T-cells (CTL019 therapy) in a cohort of 28 patients with refractory or relapsed diffuse large B-cell lymphoma or follicular lymphoma. Primary outcomes included response to treatment and evidence of toxic effects at 3 months post-treatment. Complete remission was observed in over half the patients at 3 months post treatment, and remission was maintained in many patients at 28.6 months post CTL019-treatment for both variants of non-Hodgkin's lymphoma. Adverse events were also noted, including over half of treated patients experiencing cytokine release syndrome and/or neurotoxicity, with some patients experiencing severe cases of these adverse events.

Click to read the study in NEJM

Relevant Reading: Cellular immunotherapy in B-cell malignancy

In-Depth [case-series]: This case-series study enrolled 38 patients between 2014 to 2016, of which 28 ultimately received CTL019 T-cell therapy. Adult patients with either diffuse B-cell lymphoma or follicular lymphoma who had no further treatment options, an estimated survival time of 2 years or less, and who had refractory or relapsed disease after undergoing primary and salvage therapies were eligible. All patients underwent customized T-cell lymphodepletion regimens followed by CTL019 infusion. Patients were followed for a median of 28.6 months and were assessed for progression-free survival, response to treatment, and overall survival. At three months post-treatment, 18 of 28 (64%) patients had a noticeable response to treatment (95% confidence interval [CI], 44-81%), including 7 of 14 (50%) patients with diffuse large B-cell lymphoma (95% CI, 23-77%) and 11 of 14 (79%) patients with follicular lymphoma (95% CI, 49-95%). Though the median progression-free survival was not reached by the end of the study period, 57% of patients remained progression-free after 28.6 months (95% CI, 36-73%). Patients with follicular lymphoma did not reach median progression-free survival and 70% were progression-free at 28.6 months (95% CI, 38-88%). Median progression-free survival was 3.2 months for patients with diffuse large B-cell lymphoma (95% CI, 0.9 to not reached). At the median follow-up time, it was noted that 86% of patients with diffuse large B-cell lymphoma and 89% of patients with follicular lymphoma who had an initial treatment response maintained a treatment response (95% CI, 33-98% for diffuse large B-cell lymphoma; 95% CI, 43-98% for follicular lymphoma). Median overall survival was 22.2 months for patients with diffuse large B-cell lymphoma; the median overall survival was not reached among patients with follicular lymphoma and 93% of patients were alive at the median follow-up time. The main toxic effects noted were cytokine release syndrome and encephalopathy, of which 16 and 11 total cases were noted, respectively. Five of 16 patients had severe cytotoxic release syndrome; three of 11 patients had severe encephalopathy, which later resulted in one fatality.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Share this content:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs